Refine by
Clinical Proteomics Identifying And Developing Technology
35 companies found
Technologybased inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
Technologybased inSeattle, WASHINGTON (USA)
Headquartered in Seattle, Avaden Biosciences operates the largest human biosample network in the world. Our U.S.-based partnerships with over 200 CLIA/CAP accredited facilities provide immediate access to more than 35,000,000 highly annotated ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Technologybased inNewtown, PENNSYLVANIA (USA)
Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...
Technologybased inSouth San Francisco, CALIFORNIA (USA)
At UNITY we are developing therapeutics to slow, halt, or reverse diseases of aging. Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial ...
UBX1325, a potent Bcl-xL inhibitor, is in clinical development for the treatment of age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX1325 is designed ...
Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
We have also developed another class of compounds that are novel histone deacetylase inhibitors (HDACi). Designated as our LB-200 series of compounds, these have potential use in the prevention and treatment of neurodegenerative diseases. The series ...
Technologybased inThousand Oaks, CALIFORNIA (USA)
Amgen is one of the world™s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. Amgen is committed to ...
Technologybased inMontclair, NEW JERSEY (USA)
Theranica develops advanced, clinically proven, safe and affordable digital therapeutics, addressing some of the world’s most prevalent neurological pain diseases. We harness a pain inhibition mechanism known as Conditioned Pain Modulation (CPM). ...
Technologybased inHouston, TEXAS (USA)
ScyMed is a medical information technology company developing medical decision systems and clinical Apps for Physicians and healthcare professionals. (EMR | cloud | mobile). ScyMed is @ the core of clinical processes! developing medical apps that ...
Technologybased inPuchheim, GERMANY
Originally founded in 1998 as an independent entity by Horst Lindhofer, we have assisted in the preclinical and clinical development of all Triomab® antibodies that are under development or received market approval, including that of Removab®, the ...
Technologybased inGranada, SPAIN
Regemat 3D makes available to research and science a technology tailormade designed what born to integrate the advantages of the additive manufacturing with tissue engineering and applied to the regenerative medicine. The personalized configuration ...
Technologybased inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
GW is committed to developing new medicines to treat rare, treatment-resistant epilepsy conditions where there are limited or in some cases, no approved treatment ...
Technologybased inLausanne, SWITZERLAND
Amazentis is an innovative life science company dedicated to employing breakthrough research and clinical science to bring advanced therapeutic nutrition products to life. We employ rigorous science to pioneer the discovery and clinical development ...
Technologybased inSkien, NORWAY
Different types of physical disabilities may affect, either temporarily or permanently, a person’s physical capacity and mobility. In addressing the health-related implications this may cause, we provide the opportunity for physical activity ...
Technologybased inMünchen, GERMANY
We are an interdisciplinary team with a focus on research, translation, clinical development, manufacturing, and commercialization. Our passionate team is committed to provide safe and effective tumor therapy. We are supported by a strong scientific ...
Technologybased inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
Technologybased inBrooklyn, NEW YORK (USA)
Synchron, an endovascular brain interface company, is a leader in implantable neural interface technology. The clinical-stage company is developing a neuroprosthesis for the treatment of paralysis and the first endovascular implantable ...
Technologybased inCA, CALIFORNIA (USA)
Alume Biosciences is a clinical stage biotechnology company developing nerve specific targeting molecules for intraoperative imaging. In addition to ALM-488, Alume is developing other nerve specific agents for diagnostic and therapeutic indications. ...
Technologybased inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
CBD has the potential to influence many of the key pathways involved in Glioblastoma pathogenesis, from tumor stemness and proliferation to angiogenesis and local invasion. Glioblastoma tumors express CB2 receptors, through which CBD and other ...
Technologybased inIndianapolis, INDIANA (USA)
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed ...
